Senior Counsels Jason Drori and Simon Elliott contributed an article to IPPro Patents, “The PRICED Act: A Bold Attempt to Change the Biologics Market,” on August 17, 2016. The article examined the Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act proposed legislation that aims to reduce the market exclusivity period for new biologics from 12 to seven years in the United States. Drori and Elliott discussed how the PRICED Act may be a more direct threat to the biologics industry and risks upsetting a delicate balance.
Related Insights
April 20, 2026
Energy Current
Texas Navigates Grid Reliability, Data Center Expansion, and Capital Investment Amid Rapid Energy Transformation
Key Takeaways Texas is operationally strong today, but grid reliability will increasingly depend on whether the state can add power fast…
April 20, 2026
Health Care Law Today
New Federal Focus on Fraud, Waste and Abuse May Signal Changes for the Health Care Industry
Congress and the Trump Administration have issued a series of heightened warnings indicating an emerging effort to crack down on what it terms rampant “fraud, waste, and abuse” in the health care industry. All industry stakeholders should be aware of this new focus, which not only signals potentially heightened scrutiny and enhanced penalties for compliance issues but also potential policy changes intended to reduce federal expenditures on programs or practices that are identified as improper or wasteful.
April 20, 2026
Foley Viewpoints
Final Rule Exempts ICHRAs and Other Account-Based Plans from Medicare Part D-Creditable Coverage Notice
On April 6, 2026, the Department of Health and Human Services (HHS) published a final rule formally excluding account-based group health…